Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Extension Study of Ataluren in Nonsense Mutation Dystrophinopathy
2013-005489-20Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ataluren in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and dystrophinopathy, sponsored by PTC Therapeutics, Inc. Primary endpoint: Long-term safety profile of ataluren. Started Jul 2014; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)dystrophinopathy
Beyond the preview
Go deeper on 2013-005489-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005489-20.